NRX Pharmaceuticals Inc [NASDAQ: NRXP] surged by $0.14 during the normal trading session on while it closed the day at $0.66. The company report on March 4, 2024 at 8:30 AM that NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression.
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression.
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter.
NRX Pharmaceuticals Inc stock has also gained 125.51% of its value over the past 7 days. However, NRXP stock has inclined by 80.65% in the 3 months of the year. Over the past six months meanwhile, it has gained 122.48% and gained 44.13% year-on date.
The market cap for NRXP stock reached $60.78 million, with 66.44 million shares outstanding and 61.08 million shares in the current float. Compared to the average trading volume of 1.32M shares, NRXP reached a trading volume of 12980729 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about NRX Pharmaceuticals Inc [NRXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NRXP shares is $3.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NRXP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
NRXP stock trade performance evaluation
NRX Pharmaceuticals Inc [NRXP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 125.51. With this latest performance, NRXP shares gained by 74.93% in over the last four-week period, additionally plugging by 122.48% over the last 6 months – not to mention a drop of -17.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NRXP stock in for the last two-week period is set at 71.16, with the RSI for the last a single of trading hit 76.08, and the three-weeks RSI is set at 67.96 for NRX Pharmaceuticals Inc [NRXP]. The present Moving Average for the last 50 days of trading for this stock 0.4367, while it was recorded at 0.4570 for the last single week of trading, and 0.3926 for the last 200 days.
NRX Pharmaceuticals Inc [NRXP]: An insightful look at the core fundamentals
NRX Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.68 and a Current Ratio set at 0.68.
Earnings per share (EPS) analysis for NRX Pharmaceuticals Inc [NRXP] stock
With the latest financial reports released by the company, NRX Pharmaceuticals Inc posted -0.16/share EPS, while the average EPS was predicted by analysts to be reported at -0.14/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -14.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NRXP.
NRX Pharmaceuticals Inc [NRXP]: Institutional Ownership
The top three institutional holders of NRXP stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in NRXP stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in NRXP stock with ownership which is approximately 5.8325%.
